Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS-SLE extension study of ianalumab in systemic lupus erythematosus
MOH_2025-04-23_014050Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Novartis. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
ianalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2025-04-23_014050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-23_014050.